Theratechnologies Inc. (THTX)
NASDAQ: THTX · Real-Time Price · USD
1.400
+0.065 (4.64%)
At close: Apr 1, 2025, 4:00 PM
1.410
+0.010 (0.71%)
After-hours: Apr 1, 2025, 4:41 PM EDT

Company Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.

The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.

The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema.

The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Theratechnologies Inc.
Theratechnologies logo
Country Canada
Founded 1993
Industry Biotechnology
Sector Healthcare
Employees 103
CEO Paul Lévesque

Contact Details

Address:
2015 Peel Street, 11th Floor
Montreal, QC H3A 1T8
Canada
Phone 514-336-7800
Website theratech.com

Stock Details

Ticker Symbol THTX
Exchange NASDAQ
Fiscal Year December - November
Reporting Currency USD
CIK Code 0001512717
CUSIP Number 88338H100
ISIN Number CA88338H7040
SIC Code 2834

Key Executives

Name Position
Paul Lévesque President, Chief Executive Officer and Director
Philippe Dubuc M.B.A., MBA Senior Vice President and Chief Financial Officer
Jocelyn Lafond L.L.M., LL.B. General Counsel and Corporate Secretary
Dr. Christian Marsolais Ph.D. Senior Vice President and Chief Medical Officer
John Leasure Global Commercial Officer
Joanne Choi Senior Director of Investor Relations
Hon. Andre Dupras M.Sc. Vice President of Human Resources

Latest SEC Filings

Date Type Title
Apr 1, 2025 6-K Report of foreign issuer
Mar 26, 2025 6-K Report of foreign issuer
Feb 26, 2025 20-F Annual and transition report of foreign private issuers
Feb 26, 2025 6-K Report of foreign issuer
Feb 21, 2025 6-K Report of foreign issuer
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 6-K Report of foreign issuer
Feb 14, 2025 6-K Report of foreign issuer
Feb 10, 2025 SCHEDULE 13G/A Filing
Jan 10, 2025 6-K Report of foreign issuer